Rachel Hunter, MD
Surgical Oncology · Mobile, ALNPI 1952720849
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 26.5% of the total. Reporting peaked in 2023 at $341 and has fallen 61.5% since, to $131 in 2025. That places this record below the midpoint for surgical oncology clinicians in AL, where the typical reported total is $1,095.
Across 33 payments — averaging $27.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$241
- Eisai Inc.$85
- Regeneron Healthcare Solutions, Inc.$79
- Seagen Inc.$54
- Hologic Sales And Service, LLC$48
- Stemline Therapeutics Inc.$41
- plus $363 from 15 others
What the payments were for
- Food & beverage$910100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 2 | $241 |
| Eisai Inc. | 4 | $85 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Seagen Inc. | 2 | $54 |
| Hologic Sales And Service, LLC | 1 | $48 |
| Stemline Therapeutics Inc. | 2 | $41 |
| Integra Lifesciences Corporation | 1 | $38 |
| Exelixis Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Mentor Worldwide LLC | 2 | $33 |
| Johnson & Johnson(2 entities) | 2 | $32 |
| Merck | 1 | $27 |
| Incyte Corporation | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Sanofi | 1 | $20 |
| Sobi, Inc | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Genmab U.S., Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Polynovo North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$241
How this compares
$910 in reported general payments places this provider in the 45th percentile of 26 surgical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 15 | $36 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Mobile
- John HowardMobile$20K
- Joe LilesMobile$4K
- Udai SibiaMobile$3K
- Natalie BathMobile$2K
- Mercy JimenezMobile$2K
- Martin HeslinMobile$1K
- Lee ThompsonMobile$1K
- Jillian McCabeMobile$817
- Sophie DreamBirmingham$39K
- Annabelle FonsecaBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.